- Email: [email protected]
Secretion of androgens and estrogens by normal and neoplastic ovaries in postmenopausal women
346
Citations from the Literature
women 35 years of age and older. Results indicate an increase in incidence in the younger age group in the three prairie provinces only. Cytologic histories are similar except for an increase in false negative reports in the younger age group. Clinical behavior of the disease is similar for both age groups. Cervical intraepithelial neoplasia and condyloma: An analysis of diagnostic accuracy of posttreatment follow-up methods Falcone T; Ferenczy A Department of Obstetrics and Gynecology, The Sir Mortimer B. Davis Jewish General Hospital, Montreal, Que. H3T lE2, Canada AM. J. OBSTET. GYNECOL.; 154/2 (260-264) 1986
The appropriate followup method of patients treated for cervical intraepithelial neoplasia and condyloma is controversial. One school of thought favors cytologic testing alone, whereas the other favors cytologic testing combined with colposcopy. We have analyzed the records of 750 patients treated for cervical intraepithelial neoplasia or condyloma or both in our Colposcopy Clinic. Cytologic testing, colposcopy, and histologic examination were done routinely at 3 to 4,6 to 8, and 12 to 15 months after treatment of the above conditions in 750 patients. Totals of 95% and 5% of all 128 persistent lesions were detected by histologic examination at the first (3 to 4 months) and second (6 to 8 months) posttreatment visits, respectively. The combined false negative rates for both visits were 23% for cytologic testing, 8% for colposcopy, and 5% for histologic examination. False negative rates at first visit were 1.5% for colposcopy combined with cytologic testing. These observations suggest that colposcopy and, if appropriate, histologic examination significantly contribute to cytologic testing for diagnosing the majority of persistent disease during the fist posttreatment visit. Cytologic testing alone seems to be sufficient for the subsequent follow-up of patients treated for cervical intraepithelial neoplasia and/or condyloma.
GYNECOLOGICAL ENDOCRINOLOGY Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic ovaries Pasquali R; Fabbri R; Venturoli S; et al First Institute of Internal Medicine, 40130 Bologna, Italy
University of Bologna,
AM. J. OBSTET. GYNECOL.; 154/l (139-144) 1986 This study was performed in two randomly defmedgroups of obese patients with polycystic ovaries to investigate the overall effects of hypocaloric diet combined (group 2) or not combined (group 1) with an antiandrogenic therapy (cyproterone acetate, 50 mg/day, plus ethinyl estradiol, 0.05 mg/ day) on sex hormone plasma levels, insulin secretion and resistance, and body weight loss and on their reciprocal interrelationships. All obese patients with polycystic ovaries showed elevated luteinizing hormone and androgen levels, hyperinsulinemia, and marked insulin resistance. After an average period of 3 months both groups showed a similar weight loss and a similar reduction in the insulin-resistant state. During treatment in group 1 three patients had a greater Int J Gynaecol Obstet 25
frequency of menstrual bleeding, and in one of them an ovulatory cycle was documented. Whereas, no changes in gonadotropin and sex steroid levels were found in group 1, a significant fall was observed in group 2. No relationships were observed between these changes and those which occurred on insulin levels. We conclude that hyperandrogenism in obese patients with polycystic ovaries does not appear to be a primary factor leading to the insulin-resistant state. Secretion of androgens and estrogens by normal and neoplastic ovaries in postmenopausal women Aiman J; Forney JP; Parker CR Jr Department of Obstetrics and Gynecology, The Medical College of Wisconsin, Milwaukee, WI 53226, USA
OBSTET. GYNECOL.; 68/l (l-5) 1986 Peripheral and ovarian venous concentrations of testosterone, androstenedione, estradiol-17beta and estrone were measured in 30 postmenopausal women. Ovarian venous concentrations of testosterone and estradiol-17beta were 5.6 and 4.3 times the peripheral concentrations of women with normal ovaries. This suggests that the ovaries of postmenopausal women continue to secrete these two steroids. Mean peripheral testosterone concentrations in 14 postmenopausal women with a nonfunctional or functional ovarian tumor were increased significantly. Ovarian venous concentrations of these four steroids from the side draining the tumor-bearing ovary were increased in 40 to 80% of the women. The venous concentrations from the normal ovary were also increased in 22% or more of the women an ovarian tumor. Any ovarian neoplasm in postmenopausal women may be associated with increased ovarian sex-steroid secretion. Luteinizing hormone receptors in human ovarian follicles and corpora lutea during the menstrual cycle Yamoto M; Nakano R; Iwasaki M; et al Department of Obstetrics and Gynecology, cal College, Wakayama 640, Japan
Wakayama Medi-
OBSTET. GYNECOL.; 68/2 (200-203) 1986 The binding of rzSI-labeled human luteinizing hormone (hLH) to the 2000-g fraction of human ovarian follicles and corpora lutea during the entire menstrual cycle was examined. Specific high affinity, low capacity receptors for hLH were demonstrated in the 2000g fraction of both follicles and corpora lutea. Specific binding of ‘r51-labeled hLH to follicular tissue incrased from the early follicular phase to the ovulatory phase. Specific binding of llsI-labeled hLH to luteal tissue increased from the early luteal phase to the midluteal phase and decreased towards the late luteal phase. The results of the present study indicate that the increase and decrease in receptors for hLH during the menstrual cycle might play an important role in the regulation of the ovarian cycle. Corticotropin-releasing factor can stimulate gonadotropin secretion by human fetal pituitaries in superfusion Blumenfeld Z; Kuhn RW; Jaffe RB Reproductive Endocrinology Center, Department of Obstetrics and Gynecology, University of California, San Francisco, CA, USA
AM. J. OBSTET. GYNECOL.; 154/3 (606-612) In previous studies, corticotropin-releasing
1986 factor
was
Citations from the Literature
women 35 years of age and older. Results indicate an increase in incidence in the younger age group in the three prairie provinces only. Cytologic histories are similar except for an increase in false negative reports in the younger age group. Clinical behavior of the disease is similar for both age groups. Cervical intraepithelial neoplasia and condyloma: An analysis of diagnostic accuracy of posttreatment follow-up methods Falcone T; Ferenczy A Department of Obstetrics and Gynecology, The Sir Mortimer B. Davis Jewish General Hospital, Montreal, Que. H3T lE2, Canada AM. J. OBSTET. GYNECOL.; 154/2 (260-264) 1986
The appropriate followup method of patients treated for cervical intraepithelial neoplasia and condyloma is controversial. One school of thought favors cytologic testing alone, whereas the other favors cytologic testing combined with colposcopy. We have analyzed the records of 750 patients treated for cervical intraepithelial neoplasia or condyloma or both in our Colposcopy Clinic. Cytologic testing, colposcopy, and histologic examination were done routinely at 3 to 4,6 to 8, and 12 to 15 months after treatment of the above conditions in 750 patients. Totals of 95% and 5% of all 128 persistent lesions were detected by histologic examination at the first (3 to 4 months) and second (6 to 8 months) posttreatment visits, respectively. The combined false negative rates for both visits were 23% for cytologic testing, 8% for colposcopy, and 5% for histologic examination. False negative rates at first visit were 1.5% for colposcopy combined with cytologic testing. These observations suggest that colposcopy and, if appropriate, histologic examination significantly contribute to cytologic testing for diagnosing the majority of persistent disease during the fist posttreatment visit. Cytologic testing alone seems to be sufficient for the subsequent follow-up of patients treated for cervical intraepithelial neoplasia and/or condyloma.
GYNECOLOGICAL ENDOCRINOLOGY Effect of weight loss and antiandrogenic therapy on sex hormone blood levels and insulin resistance in obese patients with polycystic ovaries Pasquali R; Fabbri R; Venturoli S; et al First Institute of Internal Medicine, 40130 Bologna, Italy
University of Bologna,
AM. J. OBSTET. GYNECOL.; 154/l (139-144) 1986 This study was performed in two randomly defmedgroups of obese patients with polycystic ovaries to investigate the overall effects of hypocaloric diet combined (group 2) or not combined (group 1) with an antiandrogenic therapy (cyproterone acetate, 50 mg/day, plus ethinyl estradiol, 0.05 mg/ day) on sex hormone plasma levels, insulin secretion and resistance, and body weight loss and on their reciprocal interrelationships. All obese patients with polycystic ovaries showed elevated luteinizing hormone and androgen levels, hyperinsulinemia, and marked insulin resistance. After an average period of 3 months both groups showed a similar weight loss and a similar reduction in the insulin-resistant state. During treatment in group 1 three patients had a greater Int J Gynaecol Obstet 25
frequency of menstrual bleeding, and in one of them an ovulatory cycle was documented. Whereas, no changes in gonadotropin and sex steroid levels were found in group 1, a significant fall was observed in group 2. No relationships were observed between these changes and those which occurred on insulin levels. We conclude that hyperandrogenism in obese patients with polycystic ovaries does not appear to be a primary factor leading to the insulin-resistant state. Secretion of androgens and estrogens by normal and neoplastic ovaries in postmenopausal women Aiman J; Forney JP; Parker CR Jr Department of Obstetrics and Gynecology, The Medical College of Wisconsin, Milwaukee, WI 53226, USA
OBSTET. GYNECOL.; 68/l (l-5) 1986 Peripheral and ovarian venous concentrations of testosterone, androstenedione, estradiol-17beta and estrone were measured in 30 postmenopausal women. Ovarian venous concentrations of testosterone and estradiol-17beta were 5.6 and 4.3 times the peripheral concentrations of women with normal ovaries. This suggests that the ovaries of postmenopausal women continue to secrete these two steroids. Mean peripheral testosterone concentrations in 14 postmenopausal women with a nonfunctional or functional ovarian tumor were increased significantly. Ovarian venous concentrations of these four steroids from the side draining the tumor-bearing ovary were increased in 40 to 80% of the women. The venous concentrations from the normal ovary were also increased in 22% or more of the women an ovarian tumor. Any ovarian neoplasm in postmenopausal women may be associated with increased ovarian sex-steroid secretion. Luteinizing hormone receptors in human ovarian follicles and corpora lutea during the menstrual cycle Yamoto M; Nakano R; Iwasaki M; et al Department of Obstetrics and Gynecology, cal College, Wakayama 640, Japan
Wakayama Medi-
OBSTET. GYNECOL.; 68/2 (200-203) 1986 The binding of rzSI-labeled human luteinizing hormone (hLH) to the 2000-g fraction of human ovarian follicles and corpora lutea during the entire menstrual cycle was examined. Specific high affinity, low capacity receptors for hLH were demonstrated in the 2000g fraction of both follicles and corpora lutea. Specific binding of ‘r51-labeled hLH to follicular tissue incrased from the early follicular phase to the ovulatory phase. Specific binding of llsI-labeled hLH to luteal tissue increased from the early luteal phase to the midluteal phase and decreased towards the late luteal phase. The results of the present study indicate that the increase and decrease in receptors for hLH during the menstrual cycle might play an important role in the regulation of the ovarian cycle. Corticotropin-releasing factor can stimulate gonadotropin secretion by human fetal pituitaries in superfusion Blumenfeld Z; Kuhn RW; Jaffe RB Reproductive Endocrinology Center, Department of Obstetrics and Gynecology, University of California, San Francisco, CA, USA
AM. J. OBSTET. GYNECOL.; 154/3 (606-612) In previous studies, corticotropin-releasing
1986 factor
was